Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: Updated results from the phase 1/2 BRUIN study Meeting Abstract


Authors: Wang, M.; Shah, N.; Alencar, A.; Gerson, J.; Patel, M.; Fakhri, B.; Jurczak, W.; Tan, X.; Lewis, K.; Fenske, T.; Coombs, C.; Flinn, I.; Lewis, D.; Le Gouill, S.; Palomba, M. L.; Woyach, J.; Pagel, J.; Lamanna, N.; Cohen, J.; Barve, M.; Ghia, P.; Eyre, T.; Zinzani, P. L.; Ujjani, C.; Koh, Y.; Izutsu, K.; Lech-Maranda, E.; Tam, C.; Sundaram, S.; Yin, M.; Nair, B.; Tsai, D.; Balbas, M.; Mato, A.; Cheah, C.
Abstract Title: Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: Updated results from the phase 1/2 BRUIN study
Meeting Title: 62nd Annual Scientific Meeting of the British Society for Haematology
Journal Title: British Journal of Haematology
Volume: 197
Issue: Suppl. 1
Meeting Dates: 2022 Apr 3-5
Meeting Location: Manchester, United Kingdom
ISSN: 0007-1048
Publisher: John Wiley & Sons  
Date Published: 2022-05-01
Start Page: 101
End Page: 104
Language: English
ACCESSION: WOS:000776484300106
PROVIDER: wos
PUBMED: 35362090
DOI: 10.1111/bjh.18134
Notes: Meeting Abstract: BSH22-PO56 -- Hybrid meeting, also held virtually -- Source: Wos
Altmetric
Citation Impact
MSK Authors
  1. Maria Lia Palomba
    248 Palomba
  2. Anthony R Mato
    145 Mato